Sanofi Sa · EURONEXT:SAN
Sanofi Sa — Q3 2022 Earnings Presentation
57 slides from Sanofi Sa's earnings presentation, Oct 28, 2022
Slide 1: Performance through transformation
Performance through transformation Business update Financial performance Outlook 2022 Appendices
Slide 2: Q3 2022 Results
Performance through transformation Business update Financial performance Outlook 2022 Appendices Q3 2022 Results Play to Win October 28, 2022
Slide 3: Forward-looking statements
Performance through transformation Business update Financial performance Outlook 2022 Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements tha
Slide 4: Agenda
Performance through transformation Business update Financial performance Outlook 2022 Appendices Agenda 01 Performance through transformation Paul Hudson 02 Business update Bill Sibold, Thomas Triomphe, Olivier Charmeil & Julie Van Ongevalle 03 Financial performance and outlook Jean-Baptiste de Chat
Slide 5: Performance through transformation
Performance through transformation Business update Financial performance Outlook 2022 Appendices Performance through transformation
Slide 6: Specialty Care and Vaccines drive 9.0% sales growth in Q3
Performance through transformation Business update Financial performance Outlook 2022 Appendices Specialty Care and Vaccines drive 9.0% sales growth in Q3 Specialty Care Vaccines GenMed Specialty Care Dupixent® Q3 growth driven €4.4bn €3.3bn €3.5bn by new launches +19.9% +23.5% -8.5% Vaccines Core a
Slide 7: Higher sales in the largest healthcare market
Performance through transformation Business update Financial performance Outlook 2022 Appendices Higher sales in the largest healthcare market Specialty Vaccines GenMed Inflation Reduction Expected Sanofi business Care Core assets Act (IRA) impact +24.4% Inflation Industry leadership in penalties re
Slide 8: On track for key launches in 2023
Performance through transformation Business update Financial performance Outlook 2022 Appendices On track for key launches in 2023 • Efanesoctcog alfa, a once-weekly prophylaxis, • CHMP positive opinion of Beyfortus®C (nirsevimab) provided superior bleed protection with clinically for prevention of
Slide 9: Progress in R&D transformation with a focus on key areas
Performance through transformation Business update Financial performance Outlook 2022 Appendices Progress in R&D transformation with a focus on key areas NME in Phase 1-3 by Q3 External innovation 35 Vaccines 30 Oncology research collaboration to Neurology enable genetic modification of novel 25 nat
Slide 10: Upcoming newsflow over the next 18 months
Performance through transformation Business update Financial performance Outlook 2022 Appendices Upcoming newsflow over the next 18 months 9 Phase 3/pivotal readouts 27 Phase 1-2 readouts Dupixent®A amlitelimab Atopic Dermatitis tusamitamab ravtansine SAR442257 COPD Gastric cancer MM / N-H Lymphoma
Slide 11: Sanofi championing efforts in decarbonizing the patient journey
Performance through transformation Business update Financial performance Outlook 2022 Appendices Sanofi championing efforts in decarbonizing the patient journey to be showcased at COP27 5% Aim to deliver net zero patient care through healthcare stakeholder engagement and new way to deliver healthcar
Slide 12: Business update
Performance through transformation Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Business update Q3 2022
Slide 13: Specialty Care performance
Performance through transformation Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Specialty Care performance €4.4bn sales +19.9% Q3 2022 Dupixent® Oncology Dupixent® Strong performance driven by increase in demand €224m €2,314m and gr
Slide 14: Dupixent growth trajectory continues to impress in Q3
Performance through transformation Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Dupixent growth trajectory continues to impress in Q3 ® Global Dupixent® sales (€m) Performance highlights in Q3 Ex-U.S. Worldwide growth of Ex-U.S. ann
Slide 15: Leading in specialty dermatology
Performance through transformation Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Leading in specialty dermatology A pool of biologics eligible ~5m patients Prurigo Nodularis Expanding dermatology Chronic and debilitating skin disease
Slide 16: Nexviazyme: Launch excellence in Pompe
Performance through transformation Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Nexviazyme : Launch excellence in Pompe ® Global Pompe disease sales (€m) Nexviazyme® launch progress across U.S., Japan and Australia ahead of expectat
Slide 17: Sarclisa strong uptake in approved indications
Performance through transformation Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Sarclisa strong uptake in approved indications ® Newly diagnosed MM Relapsed refractory MM Sarclisa® ~65,000 YTD Sep sales €208m, +62% Transplant Eligib
Slide 18: Vaccines performance
Performance through transformation Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Vaccines performance €3.3bn sales +23.5% Q3 2022 Travel & Endemic Influenza Outstanding quarter with growth in all €146m €1,994m franchises and across a
Slide 19: Raising the bar in influenza standard of care
Performance through transformation Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Raising the bar in influenza standard of care Continuing to support Protection Beyond Flu Continuing to innovate Three Phase 1/2 studies with Associated
Slide 20: Beyfortus consistent strong efficacy and safety profile across all studies
Performance through transformation Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Beyfortus consistent strong efficacy and safety profile ® across all studies c Positive opinion from CHMP, FDA submission acceptance expected in Q4 New
Slide 21: GenMed performance
Performance through transformation Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare GenMed performance €3.5bn sales -8.5% Q3 2022 Core assets on track Core assets Robust growth of Toujeo® and Praluent® in ex-U.S. €1,586m geographies, ma
Slide 22: GenMed: Q3 2022 core assets performance
Performance through transformation Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare GenMed: Q3 2022 core assets performance € millions Q3 2021 -23.0% Q3 2022 +17.2% +43.7% -1.4% 383 307 304 239 246 230 +10.1% 222 +33.9% 151 -5.9% 101 83
Slide 23: CHC: 4 consecutive periods above market growth
Performance through transformation Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare CHC: 4 consecutive periods above market growth Growth (MAT, in %) +16.5% Exceptionally strong market growth since +15.4% +15.5% March 2021, has peaked +
Slide 24: CHC performance
Performance through transformation Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare CHC performance €1.3bn sales +1.9% Q3 2022 Digestive Pain Care Wellness €292m Q3 organic growth +3.5% €351m -3.8% Solid performance despite overall +14.
Slide 25: Standout performance for Digestive Wellness
Performance through transformation Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Standout performance for Digestive Wellness “Bellies ready” “Feel good. “Untie your belly. Inside & Out.” Untie your life” “I liver Life” CC #1 * #1 * #
Slide 26: Financial performance
Performance through transformation Business update Financial performance Outlook 2022 Appendices Financial performance Q3 2022
Slide 27: Advancing toward our net zero target
Performance through transformation Business update Financial performance Outlook 2022 Appendices Advancing toward Delivering positive impact on communities and the environment our net zero target Mangroves 19,500 tCO2e/year carbon removed over 20 years Improving biodiversity Additional income from m
Slide 28: Q3 P&L
Performance through transformation Business update Financial performance Outlook 2022 Appendices Q3 P&L €m Q3 2022 Q3 2021 % Change (CER) Net Sales 12,482 10,432 +9.0% Other revenues 656 397 +41.1% Gross profit 9,307 7,591 +10.3% Gross margin % 74.6%1 72.8%1 R&D (1,736) (1,444) +12.7% SG&A (2,644) (
Slide 29: Transformation driving strong 9M financial performance indicators
Performance through transformation Business update Financial performance Outlook 2022 Appendices Transformation driving strong 9M financial performance indicators 9M 2022 9M 2021 Change1 Sales €32.3bn €27.8bn +8.6% Gross margin 74.3% 72.0% +1.6ppt R&D spend €4.9bn €4.1bn +13.1% BOI margin 32.0% 30.5
Slide 30: Outlook
Performance through transformation Business update Financial performance Outlook 2022 Appendices Outlook H2 2022
Slide 31: Significant step up in FY 2022 profitability expected
Performance through transformation Business update Financial performance Outlook 2022 Appendices Significant step up in FY 2022 profitability expected BOI margin evolution at CER Q4 profitability levers: 1.1pts • Dupixent® 1.6pts • Capital gains from divestitures 30% • Lower marketing & selling expe
Slide 32: Upgraded 2022 FY guidance
Performance through transformation Business update Financial performance Outlook 2022 Appendices Upgraded 2022 FY guidance BOI margin EPS growth 30% around 16% growth at CER Approximately +9.5% to +10.5% currency impact1 Barring unforeseen events. 1. Based on October 2022 average rates. 32 Investor
Slide 33: Q&A session
Performance through transformation Business update Financial performance Outlook 2022 Appendices Q&A session
Slide 34: R&D appendices
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D appendices
Slide 35: Expected R&D milestones in 2022
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Expected R&D milestones in 2022 H1 2022 H2 2022 Status as of Q3 Dupixent® EoE U.S./EU regulatory submissions Approved U.S./
Slide 36: R&D Pipeline Phase III & Registration
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D Pipeline Phase III & Registration Phase III Registration Name Description Indication Name Description Indication Dupixe
Slide 37: R&D Pipeline – Phase II
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D Pipeline – Phase II Phase II Name Description Indication Name Description Indication R Kevzara®A Anti-IL-6 mAb Polyarti
Slide 38: R&D Pipeline – Phase I
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D Pipeline – Phase I Phase I Name Description Indication SAR441566 Oral TNF inhibitor Inflammatory indications SAR444656I
Slide 39: Expected submission timelines
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Expected submission timelines 2022 2023 2024 2025 and beyond ®A Dupixent®A tusamitamab Nexviazyme® Dupixent Dupixent®A Dupi
Slide 40: Reinforcing Protection Beyond Flu with data from innovative study design
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Reinforcing Protection Beyond Flu with data from innovative study design DANFLU-1 VAP03 Study • Individually-randomized pra
Slide 41: Beyfortus the first and only broadly protective option against RSV for all infants
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Beyfortus®C the first and only broadly protective option against RSV for all infants Supported by strong efficacy and safet
Slide 42: Financial appendices
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Financial appendices
Slide 43: 2022 business outlook
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations 2022 business outlook Sales Specialty Care Vaccines Growth driven by Dupixent®, Record flu season sales P&L N&I slightly do
Slide 44: 9M P&L
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations 9M P&L €m 9M 2022 9M 2021 % Change (CER) Net Sales 32,272 27,767 +8.6% Other revenues 1,661 993 +49.2% Gross profit 23,975
Slide 45: Main product sales
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Main product sales Q3 2022 sales (€m) Growth Dupixent 2,314 44.5% Influenza Vaccines (Fluzone HD, Flubok, Fluzone, Vaxigrip
Slide 46: Q3 sales and EPS
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Q3 sales and EPS Currency impact Company sales Business EPS +0.31 €661m -0.15 -0.12 -0.15 -0.11 €1,108 €341m -0.11 +0.12 +0
Slide 47: Net debt evolution in 9M 2022
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Net debt evolution in 9M 20221 € millions 9,983 4,168 -658 8,748 -6,677 872 1,736 -676 Net Debt FCF before Proceeds Asset R
Slide 48: 2022 currency sensitivity and Q3 2022 currency exposure
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations 2022 currency sensitivity and Q3 2022 currency exposure 2022 Business EPS currency sensitivity Currency exposure on Q3 2022
Slide 49: Sanofi accounting of Antibody License and Collaboration Agreement with Regeneron
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi accounting of Antibody License and Collaboration Agreement with Regeneron 1 Last updated July 2022 U.S. Ex-U.S. Net
Slide 50: Sanofi Libtayo accounting pursuant to Immuno-Oncology License and Collaboration Agreement
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi Libtayo® accounting pursuant to Immuno-Oncology License and Collaboration Agreement with Regeneron 1 Applicable befo
Slide 51: Sanofi Libtayo accounting pursuant to Amended and Restated Agreement
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi Libtayo® accounting pursuant to Amended and Restated Immuno-Oncology License and Collaboration Agreement with Regene
Slide 52: ESG appendices
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations ESG appendices
Slide 53: Sanofi ESG Q3 achievements
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi ESG Q3 achievements Affordable access R&D for unmet needs Global Health Unit #Patients treated Rare disease vials do
Slide 54: Sanofi ESG Q3 achievements
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi ESG Q3 achievements Planet care In and beyond the workplace Blister-free syringe vaccines Scope 1 & 2 Diverse Senior
Slide 55: Sanofi ESG ratings
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi ESG ratings Rating agencies SCORE Climate 21.6 86/100 69/100 A Change: A B 4.3/5 3.47/5 92% 64/100 Medium risk Water
Slide 56: Collaborations
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Collaborations Ref Name Developed in collaboration with… A Dupixent® Regeneron itepekimab Libtayo® Kevzara® B Altuviiio® So
Slide 57: Abbreviations
Performance through transformation Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Abbreviations Ab Antibody ICOS Inducible COStimulatory molecule QIV Quadrivalent Influenza vaccine AD Atopic Dermatitis IL